NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning,
Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion Therapeutics,
Inc. (NASDAQ:ESPR), Summit Therapeutics PLC (NASDAQ:SMMT), Ocwen Financial Corporation (NYSE:OCN), Keane Group, Inc. (NYSE:FRAC),
Cellectis S.A. (NASDAQ:CLLS), and Rapid7, Inc. (NASDAQ:RPD), including updated fundamental summaries, consolidated fiscal
reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
ESPR DOWNLOAD: http://Fundamental-Markets.com/register/?so=ESPR
SMMT DOWNLOAD: http://Fundamental-Markets.com/register/?so=SMMT
OCN DOWNLOAD: http://Fundamental-Markets.com/register/?so=OCN
FRAC DOWNLOAD: http://Fundamental-Markets.com/register/?so=FRAC
CLLS DOWNLOAD: http://Fundamental-Markets.com/register/?so=CLLS
RPD DOWNLOAD: http://Fundamental-Markets.com/register/?so=RPD
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine
Esperion Therapeutics, Inc. (NASDAQ:ESPR), Summit Therapeutics PLC (NASDAQ:SMMT), Ocwen Financial Corporation (NYSE:OCN), Keane
Group, Inc. (NYSE:FRAC), Cellectis S.A. (NASDAQ:CLLS), and Rapid7, Inc. (NASDAQ:RPD) on a fundamental level and outlines the
overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion,
and overall direction going forward. Several excerpts from the recently released reports are available to today's readers
below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone
summaries and as such, important information may be missing from these samples. Please download the entire research report, free of
charge, to ensure you are reading all relevant material information. All information in this release was accessed October 15th,
2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
ESPERION THERAPEUTICS, INC. (ESPR) REPORT OVERVIEW
Esperion Therapeutics' Recent Financial Performance
Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending
September 30th, 2018. The reported EPS for the same quarter last year was -$1.86. The estimated EPS forecast for the next fiscal
year is -$5.63 and is expected to report on February 19th, 2019.
To read the full Esperion Therapeutics, Inc. (ESPR) report, download it here: http://Fundamental-Markets.com/register/?so=ESPR
-----------------------------------------
SUMMIT THERAPEUTICS PLC (SMMT) REPORT OVERVIEW
Summit Therapeutics' Recent Financial Performance
For the three months ended July 31st, 2018 vs July 31st, 2017, Summit Therapeutics reported revenue of $50.51MM
vs $25.01MM (up 101.97%) and analysts estimated basic earnings per share $2.13 vs $1.15 (up 85.14%). For the twelve months ended
January 31st, 2018 vs January 31st, 2017, Summit Therapeutics reported revenue of $33.08MM vs $3.08MM (up 973.16%) and analysts
estimated basic earnings per share -$0.70 vs -$2.32. Analysts expect earnings to be released on December 5th, 2018. The report will
be for the fiscal period ending October 31st, 2018. Reported EPS for the same quarter last year was -$0.20. The estimated EPS
forecast for the next fiscal year is -$1.74 and is expected to report on April 10th, 2019.
To read the full Summit Therapeutics PLC (SMMT) report, download it here: http://Fundamental-Markets.com/register/?so=SMMT
-----------------------------------------
OCWEN FINANCIAL CORPORATION (OCN) REPORT OVERVIEW
Ocwen Financial's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Ocwen Financial reported revenue of $253.58MM vs
$311.30MM (down 18.54%) and analysts estimated basic earnings per share -$0.22 vs -$0.36. For the twelve months ended December
31st, 2017 vs December 31st, 2016, Ocwen Financial reported revenue of $1,194.58MM vs $1,387.16MM (down 13.88%) and analysts
estimated basic earnings per share -$1.01 vs -$1.61. Analysts expect earnings to be released on November 1st, 2018. The report will
be for the fiscal period ending September 30th, 2018.
To read the full Ocwen Financial Corporation (OCN) report, download it here: http://Fundamental-Markets.com/register/?so=OCN
-----------------------------------------
KEANE GROUP, INC. (FRAC) REPORT OVERVIEW
Keane Group's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Keane Group reported revenue of $578.53MM vs
$323.14MM (up 79.04%) and basic earnings per share $0.28 vs -$0.12. For the twelve months ended December 31st, 2017 vs December
31st, 2016, Keane Group reported revenue of $1,542.08MM vs $420.57MM (up 266.66%) and analysts estimated basic earnings per share
-$0.34 vs -$2.14. Analysts expect earnings to be released on October 31st, 2018. The report will be for the fiscal period ending
September 30th, 2018. The reported EPS for the same quarter last year was $0.04. The estimated EPS forecast for the next fiscal
year is $0.63 and is expected to report on February 25th, 2019.
To read the full Keane Group, Inc. (FRAC) report, download it here: http://Fundamental-Markets.com/register/?so=FRAC
-----------------------------------------
CELLECTIS S.A. (CLLS) REPORT OVERVIEW
Cellectis S.A's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Cellectis S.A reported revenue of $8.34MM vs
$8.97MM (down 6.97%) and analysts estimated basic earnings per share -$0.17 vs -$0.75. For the twelve months ended December 31st,
2017 vs December 31st, 2016, Cellectis S.A reported revenue of $33.72MM vs $56.44MM (down 40.27%) and analysts estimated basic
earnings per share -$2.78 vs -$1.91. Analysts expect earnings to be released on November 12th, 2018. The report will be for the
fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.73. The estimated EPS forecast
for the next fiscal year is -$2.36 and is expected to report on March 11th, 2019.
To read the full Cellectis S.A. (CLLS) report, download it here: http://Fundamental-Markets.com/register/?so=CLLS
-----------------------------------------
RAPID7, INC. (RPD) REPORT OVERVIEW
Rapid7's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Rapid7 reported revenue of $58.44MM vs $47.44MM
(up 23.18%) and analysts estimated basic earnings per share -$0.31 vs -$0.27. For the twelve months ended December 31st, 2017 vs
December 31st, 2016, Rapid7 reported revenue of $200.94MM vs $157.44MM (up 27.63%) and analysts estimated basic earnings per share
-$1.06 vs -$1.19. Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending
September 30th, 2018. The reported EPS for the same quarter last year was -$0.27. The estimated EPS forecast for the next fiscal
year is -$0.53 and is expected to report on February 11th, 2019.
To read the full Rapid7, Inc. (RPD) report, download it here: http://Fundamental-Markets.com/register/?so=RPD
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading
brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals
worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA®
BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst®
(CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes
qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers.
Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit
firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries
regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail
at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental
Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result
from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the
material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the
publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm,
investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full
disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network
manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority,
Inc.
